Expert consensus of anti-tumor drugs prescription review: kidney cancer [抗肿瘤药物处方审核专家共识:肾癌]

作者：Liu M.; Miao W.; Zhang C.; Zhang J.; Dai Y.; Dong M.; Liu J.; Huang H.; Zhai Q.; Liu Y.; Xu T.; Huang P.; Zhang W.; Jiang G.; Cao J.; Wang L.; Sun Y.; Jiang M.; Lyu Y.; Lu X.; Liu M.; Liang N.; Dai Z.; Song Y.; Li P.; Liu G.; Hao Z.; Yao D.; Li G.; Kong S.; Xie R.; Wang J.; Wei Q.; Jia L.; Li M.; Meng J.; Cao F.; Shi H.; Yan D.; Bai Z.; Wang C.; Li G.; He J.

来源：药物不良反应杂志, 2021, 23(6): 285-292.

DOI：10.3760/cma.j.cn114015-20210302-00248

• Carcinoma, renal cell
• Drug prescriptions
• Practice guideline

Kidney cancer usually requires multidisciplinary individualized treatments. No matter what kind of treatment, drugs are essential. According to the "six-step process" (prescription legitimacy review, patient basic information evaluation review, treatment protocol review, organ function and laboratory index review, pretreatment review, and unconventional prescription review) in prescription review proposed by the anti-tumor drug prescription review expert group and referring to domestic and foreign kidney cancer guidelines and drug instructions in recent years, this consensus selects 9 targeted drugs and 4 immunotherapeutic drugs that are currently commonly used in China and elaborates the key review points in patient basic information evaluation review, treatment protocol review, and organ function and laboratory index review of kidney cancer drug treatment, in order to provide reference for clinical front-line pharmacists to review prescriptions of kidney cancer patients and promote rational drug use in clinic.

• 单位
  浙江大学; 华中科技大学; 北京中医药大学; 复旦大学; 天津医科大学; 中医学科学院; 中国医学科学院北京协和医院; 北京协和医学院; 中山大学; 四川大学; 福建省肿瘤医院; 湖南省肿瘤医院; 陕西省肿瘤医院